Industry News Biogen / TRIMTECH Therapeutics Fierce Biotech

Biogen backs TRIM21 degraders for neurodegeneration in $411M TrimTech deal

  • Biogen pays TRIMTECH about $32 million upfront for small-molecule degraders aimed at neurodegenerative disease, with up to $411 million in total payments plus royalties.
  • It is a research, option and license structure: Biogen can take a global exclusive license to resulting degraders and then funds development and sales.
  • TRIMTECH uses the E3 ligase TRIM21 to clear toxic protein aggregates, as an alternative to conventional PROTACs; the company was founded in 2023.
Points Based on public reports

The cash that is actually committed is small, so this is an option on a mechanism, not a pipeline buy. The appeal is TRIM21's ability to act on aggregates that CRBN- or VHL-based PROTACs handle poorly. The open question is brain exposure: bivalent degraders are large, and CNS-penetrant chemistry decides whether Biogen ever exercises. Following its glue pact with Neomorph, Biogen is building a degrader portfolio on cheap options.